Oxford Immunotec Global Plc operates as a diagnostics company, which develops and commercializes proprietary tests for immunology and infectious disease. Its products include T-SPOT.TB, T-SPOT.CMV, T-SPOT.PRT and T-CELL XTEND. The company was founded by Peter James Wrighton-Smith in 2002 and is headquartered in Abingdon, the United Kingdom.
Company profile
CEO
Peter Wrighton-Smith
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Oxford Immunotec Limited • Oxford Immunotec USA, Inc. • Immunetics, Inc. • Oxford Diagnostic Laboratories (UK) Limited • Oxford Immunotec K.K. • Boulder Diagnostics Europe GmbH • Oxford Immunotec Asia Limited • Oxford Immunotec (Shanghai) Medical Device Co. Ltd. • Oxford Immunotec (Ireland) Limited ...
Latest filings (excl ownership)
15-12B
Securities registration termination
18 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 21
8-K
Completion of Acquisition or Disposition of Assets
8 Mar 21
25-NSE
Exchange delisting
8 Mar 21
8-K/A
Submission of Matters to a Vote of Security Holders
2 Mar 21
8-K
Material Modifications to Rights of Security Holders
26 Feb 21
DEFM14A
Proxy related to merger
29 Jan 21
PREM14A
Preliminary proxy related to merger
19 Jan 21
DEFA14A
Additional proxy soliciting materials
7 Jan 21
Transcripts
Earnings call transcript
2020 Q3
3 Nov 20
Earnings call transcript
2020 Q3
3 Nov 20
Earnings call transcript
2020 Q3
3 Nov 20
Earnings call transcript
2020 Q3
3 Nov 20
Earnings call transcript
2020 Q3
3 Nov 20
Earnings call transcript
2020 Q3
3 Nov 20
Earnings call transcript
2020 Q2
9 Aug 20
Earnings call transcript
2020 Q1
10 May 20
Earnings call transcript
2019 Q4
2 Mar 20
Earnings call transcript
2019 Q3
9 Nov 19
Latest ownership filings
SC 13G/A
Alyeska Investment Group, L.P.
14 Feb 22
SC 13G/A
Polar Capital Holdings Plc
14 Feb 22
SC 13G
Grandeur Peak Global Advisors, LLC
7 May 21
4
HERM ROSENMAN
12 Mar 21
4
Matthew T E McLaughlin
12 Mar 21
4
RICHARD A SANDBERG
12 Mar 21
4
Mark R. Klausner
12 Mar 21
4
Janet Louise Kidd
12 Mar 21
4
PATRICIA RANDALL
12 Mar 21
4
PATRICK J BALTHROP
12 Mar 21
Financial summary
| Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 160.72 mm | 160.72 mm | 160.72 mm | 160.72 mm | 160.72 mm | 160.72 mm |
| Cash burn (monthly) | 1.62 mm | 2.22 mm | (no burn) | 1.21 mm | 1.20 mm | 989.83 k |
| Cash used (since last report) | 79.85 mm | 109.36 mm | n/a | 59.78 mm | 59.10 mm | 48.71 mm |
| Cash remaining | 80.87 mm | 51.36 mm | n/a | 100.94 mm | 101.62 mm | 112.01 mm |
| Runway (months of cash) | 49.8 | 23.1 | n/a | 83.1 | 84.6 | 113.2 |
Institutional ownership, Q3 2021
5.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 29.15 mm |
| Total shares | 1.33 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Integrated Core Strategies | 1.33 mm | $29.15 mm |